ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
When Testosterone Is Not Enough
Beyond ED: cGMP-Specific PDE5i for Other Clinical Disorders
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 242787" data-attributes="member: 13851"><p><strong>Figure 7 <u>PDE5 inhibition in the treatment of COVID-19 and pulmonary hypertension</u>. The binding of the SARS-CoV-2 virus with its ACE2 receptor leads to excessive activation of the ACE–angiotensin II–angiotensin type 1 receptor pathway. Angiotensin II stimulates ROS with the potential depletion of NO, which triggers a proinflammatory cascade for vasoconstriction. The NO-cGMP-PKG pathway activated by treatment with PDE5 inhibitors restores NO through AMPK-mediated eNOS activation, thereby attenuating inflammation and inhibiting of platelet aggregation. PDE5 inhibitors also significantly increase pulmonary vasorelaxation and attenuate pulmonary arterial hypertension. Abbreviations: ACE2, angiotensin-converting enzyme 2; AMPK, AMP-activated protein kinase; Ang I/II, angiotensin I/II; AT1R/AT2R, angiotensin II receptor type 1/2 receptor; cGMP, cyclic guanosine monophosphate; eNOS, endothelial nitric oxide synthase; GTP, guanosine triphosphate; NO, nitric oxide; PDE5, phosphodiesterase 5; pGC, particulate guanylate cyclase; PKG, protein kinase G; ROS, reactive oxygen species; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; sGC, soluble guanylate cyclase.</strong></p><p><strong>[ATTACH=full]28312[/ATTACH]</strong></p></blockquote><p></p>
[QUOTE="madman, post: 242787, member: 13851"] [B]Figure 7 [U]PDE5 inhibition in the treatment of COVID-19 and pulmonary hypertension[/U]. The binding of the SARS-CoV-2 virus with its ACE2 receptor leads to excessive activation of the ACE–angiotensin II–angiotensin type 1 receptor pathway. Angiotensin II stimulates ROS with the potential depletion of NO, which triggers a proinflammatory cascade for vasoconstriction. The NO-cGMP-PKG pathway activated by treatment with PDE5 inhibitors restores NO through AMPK-mediated eNOS activation, thereby attenuating inflammation and inhibiting of platelet aggregation. PDE5 inhibitors also significantly increase pulmonary vasorelaxation and attenuate pulmonary arterial hypertension. Abbreviations: ACE2, angiotensin-converting enzyme 2; AMPK, AMP-activated protein kinase; Ang I/II, angiotensin I/II; AT1R/AT2R, angiotensin II receptor type 1/2 receptor; cGMP, cyclic guanosine monophosphate; eNOS, endothelial nitric oxide synthase; GTP, guanosine triphosphate; NO, nitric oxide; PDE5, phosphodiesterase 5; pGC, particulate guanylate cyclase; PKG, protein kinase G; ROS, reactive oxygen species; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; sGC, soluble guanylate cyclase. [ATTACH type="full"]28312[/ATTACH][/B] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
When Testosterone Is Not Enough
Beyond ED: cGMP-Specific PDE5i for Other Clinical Disorders
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top